| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
156,320,000 |
| Market
Cap: |
6.65(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$20.26 - $43.27 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cerevel Therapeutics Holdings is a clinical-stage biopharmaceutical company. Co.'s programs: Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype; Darigabat, which is a PAM that selectively targets the alpha-2/3/5 subunits of the GABAA receptor; Tavapadon, which is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of early- and late-stage Parkinson's disease; and CVL-871, which is a selective dopamine D1/D5 receptor partial agonist specifically designed to achieve a level of partial agonism.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
17,422,701 |
18,847,701 |
| Total Buy Value |
$0 |
$0 |
$397,510,553 |
$447,385,553 |
| Total People Bought |
0 |
0 |
6 |
6 |
| Total Buy Transactions |
0 |
0 |
6 |
7 |
| Total Shares Sold |
154,667 |
359,132 |
611,027 |
1,200,893 |
| Total Sell Value |
$6,418,967 |
$14,072,755 |
$21,003,717 |
$39,590,443 |
| Total People Sold |
2 |
8 |
8 |
10 |
| Total Sell Transactions |
5 |
21 |
27 |
48 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Renger John |
Chief Scientific Officer |
• – – |
2022-08-10 |
4 |
AS |
$40.19 |
$2,227,624 |
D/D |
(55,000) |
2,704 |
|
-23% |
|
| Renger John |
Chief Scientific Officer |
• – – |
2022-08-10 |
4 |
OE |
$3.50 |
$364,549 |
D/D |
55,000 |
57,704 |
|
- |
|
| Ceesay Abraham |
President |
• – – |
2022-08-08 |
4 |
AS |
$37.75 |
$742,024 |
D/D |
(19,211) |
0 |
|
-16% |
|
| Ceesay Abraham |
President |
• – – |
2022-08-08 |
4 |
OE |
$13.17 |
$253,009 |
D/D |
19,211 |
19,211 |
|
- |
|
| Renger John |
Chief Scientific Officer |
• – – |
2022-08-08 |
4 |
AS |
$37.75 |
$377,500 |
D/D |
(10,000) |
2,704 |
|
-16% |
|
| Renger John |
Chief Scientific Officer |
• – – |
2022-08-08 |
4 |
OE |
$3.50 |
$35,000 |
D/D |
10,000 |
12,704 |
|
- |
|
| Akamine Scott |
Chief Legal Officer |
• – – |
2022-08-08 |
4 |
AS |
$40.00 |
$400,001 |
D/D |
(10,000) |
0 |
|
-16% |
|
| Akamine Scott |
Chief Legal Officer |
• – – |
2022-08-08 |
4 |
OE |
$13.17 |
$131,700 |
D/D |
10,000 |
10,000 |
|
- |
|
| Ceesay Abraham |
President |
• – – |
2022-08-05 |
4 |
AS |
$32.50 |
$1,248,780 |
D/D |
(38,424) |
0 |
|
-24% |
|
| Ceesay Abraham |
President |
• – – |
2022-08-05 |
4 |
OE |
$13.17 |
$506,044 |
D/D |
38,424 |
38,424 |
|
- |
|
| Renger John |
Chief Scientific Officer |
• – – |
2022-08-05 |
4 |
AS |
$32.50 |
$650,000 |
D/D |
(20,000) |
2,704 |
|
-24% |
|
| Renger John |
Chief Scientific Officer |
• – – |
2022-08-05 |
4 |
OE |
$3.50 |
$70,000 |
D/D |
20,000 |
22,704 |
|
- |
|
| Renger John |
Chief Scientific Officer |
• – – |
2022-07-20 |
4 |
AS |
$30.00 |
$750,000 |
D/D |
(25,000) |
2,704 |
|
3% |
|
| Renger John |
Chief Scientific Officer |
• – – |
2022-07-20 |
4 |
OE |
$3.50 |
$87,500 |
D/D |
25,000 |
27,704 |
|
- |
|
| Renger John |
Chief Scientific Officer |
• – – |
2022-07-06 |
4 |
AS |
$32.50 |
$35,913 |
D/D |
(1,105) |
2,704 |
|
-2% |
|
| Renger John |
Chief Scientific Officer |
• – – |
2022-07-06 |
4 |
OE |
$3.50 |
$3,868 |
D/D |
1,105 |
3,809 |
|
- |
|
| Renger John |
Chief Scientific Officer |
• – – |
2022-07-05 |
4 |
AS |
$30.00 |
$750,000 |
D/D |
(25,000) |
2,704 |
|
-4% |
|
| Renger John |
Chief Scientific Officer |
• – – |
2022-07-05 |
4 |
OE |
$3.50 |
$87,500 |
D/D |
25,000 |
27,704 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2022-06-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,270 |
63,894 |
|
- |
|
| Pf Equity Holdings 1 B.v. |
10% Owner |
– – • |
2022-03-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(27,349,211) |
0 |
|
- |
|
| Renger John |
Chief Scientific Officer |
• – – |
2022-03-29 |
4 |
AS |
$35.00 |
$350,000 |
D/D |
(10,000) |
1,980 |
|
5% |
|
| Renger John |
Chief Scientific Officer |
• – – |
2022-03-29 |
4 |
OE |
$3.50 |
$35,000 |
D/D |
10,000 |
11,980 |
|
- |
|
| Renger John |
Chief Scientific Officer |
• – – |
2022-03-18 |
4 |
AS |
$32.50 |
$650,004 |
D/D |
(20,000) |
1,980 |
|
-22% |
|
| Renger John |
Chief Scientific Officer |
• – – |
2022-03-18 |
4 |
OE |
$3.50 |
$70,000 |
D/D |
20,000 |
21,980 |
|
- |
|
| Renger John |
Chief Scientific Officer |
• – – |
2022-03-16 |
4 |
AS |
$30.00 |
$750,005 |
D/D |
(25,000) |
1,980 |
|
-17% |
|
181 Records found
|
|
Page 5 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.04 (0.09%) 
